Also known as: Sift Biosciences
Sift Biosciences is a privately held biotechnology company developing a peptide-based immunotherapy platform for oncology and autoimmune disease. It combines AI, metagenomics, and high-throughput immune profiling to discover peptides that activate pre-existing memory T cells. The company was founded in 2024 as a UC Berkeley spin-out and is headquartered in San Carlos, California.
Sift Biosciences closed an oversubscribed $3.7 million pre-seed round to advance a peptide immunotherapy platform designed to activate pre-existing memory T cells. The financing will fund in vivo studies, expansion of its AI-powered discovery engine, and oncology lead selection.
Sift Biosciences, a UC Berkeley spinout, closed an oversubscribed $3.7 million pre-seed financing to advance its AI-driven peptide immunotherapy platform targeting immunologically "cold" solid tumors.
